31R.F - Revive Therapeutics Ltd.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0537
+0.0002 (+0.37%)
As of 8:04AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0535
Open0.0537
Bid0.0538 x N/A
Ask0.0737 x N/A
Day's Range0.0537 - 0.0537
52 Week Range0.0450 - 0.1720
VolumeN/A
Avg. Volume87
Market Cap4.648M
Beta (3Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire21 days ago

    Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2019

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) ("Revive" or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the three and nine months ended March 31, 2019.  The unaudited condensed interim financial statements and management's discussion and analysis for the period may be viewed on SEDAR at www.sedar.com.

  • GlobeNewswire2 months ago

    Revive Therapeutics Announces United States Patent Grant for Cannabinoid Delivery System

    TORONTO, April 17, 2019 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research,.

  • GlobeNewswire2 months ago

    Revive Therapeutics Announces Collaboration and Royalty Agreement With Richmond Cannabis Co.

    TORONTO, April 11, 2019 -- Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (OTCQB: RVVTF), a specialty cannabis company focused on the research,.

  • GlobeNewswire4 months ago

    Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2018

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) (‘Revive’ or the ‘Company’), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the three and six months ended December 31, 2018.  The unaudited condensed interim consolidated financial statements and related interim management's discussion and analysis for the period may be viewed on SEDAR at www.sedar.com.

  • GlobeNewswire4 months ago

    Revive Closes Over 1.4 Million in Non-Brokered Private Placement

    Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (RVVTF) is pleased to announce that it has completed the second tranche of the previously announced in the December 7, 2018, January 23, 2019 and February 4, 2019 news releases non-brokered private placement of units of the Company (“Units”), at a price of $0.10 per Unit (the “Offering”). The second tranche of the Offering consisted of the sale of 3,050,000 Units, for the aggregate gross proceeds of both tranches of the Offering of $1,401,000.

  • GlobeNewswire4 months ago

    Revive Announces Closing of the First Tranche of Its Non-Brokered Private Placement for Total Gross Proceeds of Over $1 Million

    Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (RVVTF) is pleased to announce that it has completed the first tranche of the non-brokered private placement previously announced in the December 7, 2018 and January 23, 2019 news releases for a total of 10,960,000 units (“Units”), at a price of $0.10 per Unit for gross proceeds of $1,096,000. Each Unit consisted of one common share of Revive (a “Common Share”) and one whole Common Share purchase warrant (each warrant, a “Warrant”).  Each Warrant entitles the holder to acquire one Common Share for $0.15 per Common Share for 24 months following closing of the Offering.  Eligible finders were paid a cash fee of 6% of the gross proceeds from the Units sold with their assistance and were issued Warrants  equal to 6% of the number of Units sold with their assistance.

  • GlobeNewswire5 months ago

    Revive Provides an Update on the Non-Brokered Private Placement

    Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (RVVTF) in accordance with the requirements of the policies of the TSX Venture Exchange, wishes to announce an update to the previously announced in December 7, 2018 news release of the non-brokered private placement of units (“Units”) at a price of $0.10 per Unit for gross proceeds of up to $2,000,000, subject to Company’s 20% overallotment option (the “Offering”). The Company announces a change in the terms of the Offering by increasing the previously announced one-half of a common share purchase warrant comprising the Unit to a full common share purchase warrant.  Each Unit will now consist of one common share of Revive (a “Common Share”) and one whole Common Share purchase warrant (each whole warrant, a “Warrant”).  Each Warrant entitles the holder to acquire one Common Share for $0.15 per Common Share for 24 months following closing of the Offering.  The Company has the option to increase the size of the Offering by 20%.

  • GlobeNewswire6 months ago

    Revive Announces a $2 Million Non-Brokered Private Placement

    Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE: RVV) (RVVTF) is pleased to announce that it intends to complete a non-brokered private placement of units (“Units”) at a price of $0.10 per Unit for gross proceeds of up to $2,000,000. The Company has the option to increase the size of the Offering by 20%.

  • GlobeNewswire7 months ago

    Revive Therapeutics Announces Results for the Three Months Ended September 30, 2018

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the three months ended September 30, 2018. The unaudited condensed interim consolidated financial statements and related interim management's discussion and analysis for the three months ended September 30, 2018 may be viewed on SEDAR at www.sedar.com.

  • GlobeNewswire7 months ago

    Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

    Revive Therapeutics Ltd. (TSX VENTURE: RVV) (RVVTF) (31R.F) ("Revive" or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for cannabidiol (“CBD”) in the prevention of ischemia and reperfusion injury (“IRI”) resulting from solid organ transplantation. According to the U.S. Organ Procurement and Transplantation Network, there are approximately 115,000 patients waiting for solid organ transplants in the United States, with the four most common organs transplanted being liver, kidney, heart and lung.